←
Zymeworks Inc.1,381 posts
Zymeworks Inc. avatar

Zymeworks Inc.

@ZymeworksInc

Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases.

◷ Joined October 2015▧ 996 Photos and videos
Zymeworks Inc. avatar
Zymeworks Inc.@ZymeworksInc·7h

On World COPD Day, we recognize the millions of people worldwide living with chronic obstructive pulmonary disease (COPD), a chronic lung condition that can significantly affect daily life and quality of life. Raising awareness of COPD and the challenges faced by patients is an important step toward improving understanding, supporting those affected and advancing the search for better treatment options. Learn more about World COPD Day: goldcopd.org/world-copd-day-… #WorldCOPDDay

Post attachment
Zymeworks Inc. avatar
Zymeworks Inc.@ZymeworksInc·Nov 16

Zymeworks will be attending the Jefferies Global Healthcare Conference in London for one-on-one meetings and will participate in a fireside chat on November 17 at 9:30 am GMT. If you’ll be there, we’d love to connect — please reach out to schedule a meeting. Listen to the webcast here: ir.zymeworks.com/events/even…

Post attachment
Zymeworks Inc. avatar
Zymeworks Inc.@ZymeworksInc·Nov 13

A look back at #SITC26, where our scientists presented new preclinical research on our novel PD-1 x VEGF x IL-7 multispecific immunocytokine. The research explores an innovative approach to delivering IL-7 to PD-1-positive T cells, designed to preferentially activate anti-tumor T cells while limiting activity on bystander T cells. By advancing from PD-1 bispecific to trispecific antibodies, this approach also aims to address some of the clinical limitations of current checkpoint inhibitor strategies. Read the poster: zymeworks.com/wp-content/upl…

Post attachment
Zymeworks Inc. avatar
Zymeworks Inc.@ZymeworksInc·Nov 11

Today, we honor and remember those who have served on Remembrance Day in Canada and Veterans Day in the United States. Thank you to all veterans and active service members for your dedication and sacrifice.

Post attachment
Zymeworks Inc. avatar
Zymeworks Inc.@ZymeworksInc·Nov 10

Zymeworks will present preclinical research on multispecific programs and cytokine engineering programs at PEGS Europe, taking place November 16–19 in Lisbon, Portugal. Our presentations will explore next-generation tumor-targeted masked cytokines, including conditionally active IL-12 and IL-7 x PD-1 x VEGF molecules, a multispecific approach to inflammatory disease, and a differentiated T cell engager platform. We look forward to connecting with the protein engineering community in Lisbon – learn more about our presentations: zymeworks.com/zymeworks-to-p… #PEGSEurope #antibodyengineering

Post attachment
Zymeworks Inc. avatar
Zymeworks Inc.@ZymeworksInc·Nov 8

Zymeworks will participate in upcoming investor conferences this month, engaging with members of the investment community on our strategy and portfolio. This week our schedule includes: - November 11 – @Stifel Healthcare Conference - November 12 – @Truist BioPharma Symposium We’ll also participate in the @Jefferies London Healthcare Conference next week on November 17. Visit our website for event details: lnkd.in/gzFaAHj6

Post attachment
Zymeworks Inc. avatar
Zymeworks Inc.@ZymeworksInc·Nov 6

Tomorrow at the Society for Immunotherapy of Cancer Annual Meeting, our team will present new preclinical data on a novel approach to targeted IL-7 delivery. The approach incorporates IL-7 into a multispecific antibody designed to deliver the cytokine to tumor-specific T cells, with engineering strategies intended to limit activity on bystander T cells. Presentation: Engineering targeted IL-7 delivery to enhance anti-tumor T cell fitness and persistence Abstract: 810 Date: Saturday, November 7 Location: PCC-North Building, Lower Level, Exhibition Halls 4–5–6 Learn more: zymeworks.com/zymeworks-pres… #SITC2026

Post attachment
Zymeworks Inc. avatar
Zymeworks Inc.@ZymeworksInc·Nov 4

Zymeworks will be presenting at the 2026 American Society of Hematology Annual Meeting, sharing preclinical data on ZW1953, a new CD3 multispecific T cell engager designed to target FLT3, CLEC12A, and CD33 with conditional CD28 co-stimulation for AML. Learn more: zymeworks.com/zymeworks-to-p… #ASH26

Post attachment
Zymeworks Inc. avatar
Zymeworks Inc.@ZymeworksInc·Oct 24

Today at #ESMO26 in Madrid, we shared new Phase 1 data on our investigational FRα-targeting antibody-drug conjugate in heavily pretreated patients with platinum-resistant ovarian cancer. The results reinforce our confidence in the potential of this approach to help expand treatment options for patients with ovarian cancer. Read the key data highlights here: ir.zymeworks.com/news-releas… #OvarianCancer #ADC

Post attachment
Zymeworks Inc. avatar
Zymeworks Inc.@ZymeworksInc·Oct 23

Zymeworks has entered into an exclusive global license and collaboration agreement with @Roche for ZW209, a DLL3-targeting trispecific T cell engager. Under the agreement, Zymeworks is eligible to receive a $55 million upfront payment, a $40 million payment upon initiation of the Phase 1b trial, and up to $718 million in additional development, commercial and sales-based milestones, plus tiered royalties on future global net sales. Zymeworks will conduct the Phase 1a monotherapy trial in collaboration with Roche, which will fund the trial and lead subsequent global development and commercialization. The agreement reflects Zymeworks’ strategy of advancing innovative programs through its R&D engine and partnering selected assets to share development risk while retaining meaningful participation in future success. Read the full announcement: lnkd.in/garA3Vi7 Zymeworks management will host a conference call on October 27 at 8:30 am ET. #Oncology #RocheInnovation #pRED

Post attachment
Zymeworks Inc. avatar
Zymeworks Inc.@ZymeworksInc·Oct 19

We’re pleased to welcome Suzanne Monahan to Zymeworks as Senior Vice President, Commercial and General Manager, Theravance Biopharma. Suzanne brings more than 20 years of commercial leadership experience across the pharmaceutical and medical device industries, with expertise in product launches, market access, strategic partnerships and respiratory markets. In her new role, Suzanne will lead Zymeworks’ commercial strategy and execution for YUPELRI® (revefenacin), the first and only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for the maintenance treatment of COPD. Read today's announcement: ir.zymeworks.com/news-releas…

Post attachment
Zymeworks Inc. avatar
Zymeworks Inc.@ZymeworksInc·Oct 15

Zymeworks will report its third quarter 2026 financial results on November 9, and participate in several investor conferences throughout November, including the Wolfe Research, Stifel, Truist Securities, and Jefferies Healthcare Conferences. We look forward to engaging with the investment community and sharing updates on our business and strategic priorities. Read today’s announcement: ir.zymeworks.com/news-releas…

Post attachment
Zymeworks Inc. avatar
Zymeworks Inc.@ZymeworksInc·Oct 9

Giving back to the communities where we live and work is an important part of who we are at Zymeworks. This week, employees across our hubs in Vancouver, Bellevue, New York City, Dublin, and Singapore came together for our annual all-staff giving-back event. Through hands-on activities and community initiatives, we helped bring support and a little joy to more than 1,000 children receiving care in hospitals, as well as their families and caregivers. We’re proud of what we accomplished together and grateful to everyone who gave their time and energy to make the day such a success.

Post attachment
Zymeworks Inc. avatar
Zymeworks Inc.@ZymeworksInc·Oct 2

We’re heading into a busy fall conference season, with Zymeworks researchers presenting new clinical and preclinical data across multiple medical conferences. At #ESMO26 on October 24, we’ll share new clinical results from our Phase 1 randomized dose optimization study of ZW191 in heavily pretreated patients with platinum-resistant ovarian cancer. At #SITC26, we’ll present new preclinical data on a novel approach designed to target IL-7 to tumor-specific T cells. At #PEGSEurope, we’ll showcase work across our next-generation multispecific programs and cytokine engineering. Learn more here: lnkd.in/g8iDK7bX

Zymeworks Inc. avatar
Zymeworks Inc.@ZymeworksInc·Sep 30

Today, on the National Day for Truth and Reconciliation and Orange Shirt Day, we pause to remember the children who never came home and honour Survivors, their families and communities. We recognize that reconciliation is an ongoing journey, and an opportunity to learn, reflect and build a better path forward together. We encourage everyone to take time to learn more about the history and significance of this day through resources from the National Centre for Truth and Reconciliation, today and throughout the year. Learn more: nctr.ca #NationalDayforTruthandReconciliation #OrangeShirtDay

Post attachment